Insulet Corp. Stock
Insulet Corp. Stock
We can see a decrease in the price for Insulet Corp.. Compared to yesterday it has lost -€2.700 (-1.380%).
With 50 Buy predictions and not a single Sell prediction Insulet Corp. is an absolute favorite of our community.
As a result the target price of 315 € shows a very positive potential of 63.64% compared to the current price of 192.5 € for Insulet Corp..
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Insulet Corp. stock. Negative votes have not been in the majority for any criteria for this stock
Pros and Cons of Insulet Corp. in the next few years
Pros
?
S********** s********
?
G***** c******* t* c**********
?
M***** P*******
Cons
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Insulet Corp. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Insulet Corp. | -1.380% | -5.730% | -5.822% | -14.710% | -21.171% | -32.206% | -11.819% |
| Bio-Rad Labs Inc. A | 1.210% | 0.387% | 8.106% | 1.434% | -9.500% | -48.782% | -50.128% |
| Neogen Corp. | -3.070% | -4.762% | -11.602% | -6.433% | 30.081% | - | - |
| CONMED Corp. | 0.000% | -8.092% | -9.143% | -41.111% | -9.143% | -62.367% | -69.423% |
Comments
Insulet (PODD) had its price target lowered by Citigroup Inc. from $345.00 to $338.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PODD provided by MarketBeat
Insulet (NASDAQ:PODD) had its price target lowered by analysts at Raymond James Financial, Inc. from $385.00 to $355.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for PODD provided by MarketBeat
Insulet (NASDAQ:PODD) had its price target lowered by analysts at Citigroup Inc. from $380.00 to $345.00. They now have a "buy" rating on the stock.
Show more
Ratings data for PODD provided by MarketBeat
News
Is Insulet (PODD) the Future of Diabetes Management?
Explore the exciting world of Insulet (NASDAQ: PODD) with our contributing expert analysts in this Motley Fool Scoreboard episode. Check out the video below to gain valuable insights into market
